Literature DB >> 16731439

Hyperbilirubinemia is not a major contributing factor to altered bone mineral density in patients with chronic liver disease.

Darcey L H Smith1, Norah J Shire, Nelson B Watts, Terri Schmitter, Greta Szabo, Stephen D Zucker.   

Abstract

Reduced bone density is commonly encountered in patients with chronic liver disease. Prior studies have shown that unconjugated bilirubin inhibits osteoblast activity and function in vitro and in animal models of bone mineralization. To determine whether hyperbilirubinemia promotes the development of hepatic osteodystrophy, bone mineral density (BMD) was measured by dual energy X-ray absorptiometry in a cohort of 86 consecutive patients with chronic liver disease referred for liver transplant evaluation. The mean age of the study population was 52 years (range, 22-73), in which 52% were female and 90% were white. Average bone density values were significantly lower than expected for age, race, and sex, with Z-scores for the femoral neck and spine of -0.50 (95% confidence interval [CI] -0.63 to -0.37; p=0.0003) and -0.69 (95% CI -0.85 to -0.52; p=0.0001), respectively. Sixty-one subjects (71%) exhibited reduced BMD (T-score of femoral neck or spine<or=-1 standard deviation [SD] below the young-adult mean), and 18 subjects (21%) met criteria for osteoporosis (T-score<-2.5 SD). Stepwise logistic regression analyses identified significant associations between BMD and serum creatinine, alkaline phosphatase, age, and gender. On the other hand, neither unconjugated, nor conjugated, nor total serum bilirubin levels were found to predict diminished BMD. The lack of association between serum unconjugated bilirubin levels and bone mineralization was validated in hyperbilirubinemic Gunn rats, in which BMD and serum osteocalcin levels were no different than in wild-type rodents. In conclusion, the finding that serum bilirubin levels do not correlate with reduced BMD in patients with end-stage liver disease, and that chronic unconjugated hyperbilirubinemia does not lead to alterations in bone mineralization in Gunn rats, suggests that bilirubin is not a major contributing factor to hepatic osteodystrophy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16731439     DOI: 10.1016/j.jocd.2005.10.001

Source DB:  PubMed          Journal:  J Clin Densitom        ISSN: 1094-6950            Impact factor:   2.617


  11 in total

1.  Hepatic osteodystrophy: An important matter for consideration in chronic liver disease.

Authors:  Germán López-Larramona; Alfredo J Lucendo; Sonia González-Castillo; José M Tenias
Journal:  World J Hepatol       Date:  2011-12-27

Review 2.  Osteodystrophy in chronic liver diseases.

Authors:  Pasquale Mansueto; Antonio Carroccio; Aurelio Seidita; Gaetana Di Fede; Antonio Craxì
Journal:  Intern Emerg Med       Date:  2012-01-13       Impact factor: 3.397

Review 3.  Iron homeostasis in osteoporosis and its clinical implications.

Authors:  G F Li; Y Z Pan; P Sirois; K Li; Y J Xu
Journal:  Osteoporos Int       Date:  2012-04-14       Impact factor: 4.507

4.  Association between total bilirubin and bone mineral density level in adolescents.

Authors:  Jing Wu; Jiali Su; Yangyang Wang; Jianfeng Chen; Yuanyuan Shang; Jing Li
Journal:  BMC Musculoskelet Disord       Date:  2022-07-04       Impact factor: 2.562

Review 5.  Cholestasis and metabolic bone disease - a clinical review.

Authors:  Rudolf W Gasser
Journal:  Wien Med Wochenschr       Date:  2008

Review 6.  Current understanding of osteoporosis associated with liver disease.

Authors:  Inaam A Nakchbandi; Schalk W van der Merwe
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-11       Impact factor: 46.802

Review 7.  Osteoporosis and fractures in liver disease: relevance, pathogenesis and therapeutic implications.

Authors:  Inaam A Nakchbandi
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

Review 8.  Diagnosis and Management of Cirrhosis-Related Osteoporosis.

Authors:  Lívia Alves Amaral Santos; Fernando Gomes Romeiro
Journal:  Biomed Res Int       Date:  2016-10-20       Impact factor: 3.411

9.  Osteodystrophy in Cholestatic Liver Diseases Is Attenuated by Anti-γ-Glutamyl Transpeptidase Antibody.

Authors:  Yusuke Kawazoe; Mutsumi Miyauchi; Atsuhiro Nagasaki; Hisako Furusho; Syunryo Yanagisawa; Chea Chanbora; Toshihiro Inubushi; Hideyuki Hyogo; Takashi Nakamoto; Keiko Suzuki; Sawako Moriwaki; Susumu Tazuma; Shumpei Niida; Takashi Takata
Journal:  PLoS One       Date:  2015-09-29       Impact factor: 3.240

10.  Increased risk of osteoporosis in patients with primary biliary cirrhosis.

Authors:  Chen-Yi Liao; Chi-Hsiang Chung; Pauling Chu; Kuang-Yu Wei; Tseng-Min Feng; Fu-Huang Lin; Chang-Huei Tsao; Chia-Chao Wu; Wu-Chien Chien
Journal:  PLoS One       Date:  2018-03-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.